In addition, the incidence of heart failure in HER2-positive metastatic BC patients treated with trastuzumab in combination with anthracyclines was 27%, whereas that of serious cardiovascular adverse events in the anthracycline only group was just 8%. The gene discussed is ERBB2; the disease is heart failure.